FCRL5 and Miyoshi myopathy: Moreover, anti-FcRH5 T cell-dependent bispecific antibodies have demonstrated anti-MM efficacy both in vitro and in murine xenograft models, showing near-complete and highly potent killing of primary MM plasma cells in vitro [36].